Long-term exposure to ambient air pollutant mixture and metabolic obesity phenotypes: Results from a nationwide Korean study (2007–2019)
Long-term exposure to air pollutant mixtures is associated with increased odds of metabolically unhealthy obesity (MUO), but not metabolically healthy obesity (MHO), suggesting pollution contributes to obesity-linked metabolic dysfunction.
Uncovering the connection between obesity and kidney stone disease
July 8, 2025 / obesity risk / kidney stones / metabolic health / insulin resistance / fatty liver disease
Obesity significantly increases the risk of kidney stones by promoting metabolic disturbances, including insulin resistance and liver dysfunction, which alter urinary chemistry and oxalate production—highlighting the need to treat kidney stones as a chronic metabolic condition.
Weight loss wipes out senescent fat cells but leaves immune scars, study finds
July 10, 2025 / obesity research / weight loss effects / senescent fat cells / adipose remodeling / immune scars
Weight loss eliminates senescent fat cells in metabolic and vascular tissues but leaves immune-related senescence largely intact, revealing persistent immune scars and offering new insights into adipose tissue remodeling and obesity’s resilience post-weight loss.
Beyond the Prescription: Supporting Long-Term Metabolic Health After GLP-1s
July 9, 2025 / GLP-1 transition / metabolic health / wearable technology / obesity treatment / behavior change
After GLP-1 therapy, sustained metabolic health depends on behavior change, sleep, stress management, and digital tools. Wearables offer real-time data and support to bridge the gap between clinical treatment and lasting lifestyle transformation.
Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement
July 8, 2024 / tirzepatide benefits / weight loss impact / cardiometabolic risk / obesity treatment / insulin resistance
Tirzepatide-driven cardiometabolic improvements correlate with weight loss magnitude, with benefits in blood pressure, insulin resistance, and lipids intensifying at higher weight reductions—offering clinicians clear targets for optimizing risk reduction in obesity-related care.
Age at menarche linked to cardiometabolic and reproductive health risks
Age at menarche is linked to future cardiometabolic and reproductive risks, with both early and late onset associated with distinct health outcomes, underscoring its potential as a marker for personalized prevention and early intervention strategies.
Detailed Map of Weight Loss Induced Changes in Adipose Tissue
July 9, 2025 / weight loss effects / adipose tissue remodeling / senescent cells / metabolic health / obesity research
Weight loss remodels adipose tissue by clearing senescent cells, improving lipid metabolism, and reversing obesity-related dysfunction, though some immune inflammation persists—highlighting potential targets for therapies mimicking weight loss benefits or addressing its limitations.
Your internal clock sets meal times that lower risk of obesity and diabetes
July 13, 2025 / circadian rhythm / meal timing / insulin sensitivity / type 2 diabetes / obesity risk
New study identifies factors linked to successful weight loss using GLP-1RAs
July 9, 2025 / GLP-1RA weight loss / semaglutide outcomes / obesity treatment / metabolic predictors / diabetes and weight loss
Successful weight loss with GLP-1 receptor agonists is linked to longer treatment duration, semaglutide use, absence of diabetes, higher body fat percentage, and favorable metabolic and muscle composition, highlighting potential predictors of treatment response.
Metabolic syndrome in the association of BMI and trajectory of depressive symptoms in middle-aged and elderly population: a cohort study from China
July 11, 2024 / BMI and depression / metabolic syndrome / mental health aging / underweight risks / obesity and mood
Metabolic Differences in Male and Female Muscles Influence Type 2 Diabetes
Men and women metabolize glucose and fats differently in skeletal muscle, influencing type 2 diabetes risk and exercise response. Endurance training improves metabolic performance in both sexes, supporting sex-specific approaches to diabetes prevention and personalized exercise therapy.
Hypothermia alters glucose metabolism and may reveal mechanisms of metabolic disease
July 10, 2025 / hypothermia metabolism / glucose regulation / insulin resistance / type 2 diabetes / metabolic disease
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
July 9, 2025 / metabolic weight loss / Allurion partnership / obesity care Canada / GLP-1 therapy / bariatric innovation
Okra May Protect Brain From Obesity’s Harmful Effects, New Study Finds
Obesity Reversed in Genome Edited Mice that Produce Their Own GLP-1
Researchers used genome editing to engineer mice to produce GLP-1 agonist Exendin-4 in the liver, reversing obesity and improving glucose metabolism with a single treatment—offering a potential one-time therapy for chronic metabolic diseases like obesity and type 2 diabetes.
New drug combination protects women from breast cancer and diabetes without side effects
Divamics’ AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners
Major change to health guidelines will lead to a surge in obese Americans
New obesity guidelines incorporating waist-to-hip ratio and metabolic health markers could reclassify millions of Americans as obese, replacing BMI as the sole diagnostic tool and better identifying those at risk for diabetes, heart disease, and premature death.
Does Metabolic Dysfunction-Associated Steatotic Liver Disease Affect Liver Fibrosis in Hepatitis B?
July 9, 2025 / MASLD prevalence / hepatitis B fibrosis / liver disease risk / metabolic dysfunction / type 2 diabetes
In patients with chronic hepatitis B, MASLD was present in 42.3% and significantly increased the risk of advanced liver fibrosis. Higher BMI and type 2 diabetes were independently associated with MASLD, highlighting overlapping metabolic and viral liver disease risks.
Preclinical safety data support ETX-312 for MASH human trials
July 14, 2025 / MASH treatment / ETX-312 therapy / liver fibrosis / siRNA drug / fatty liver disease
ETX-312, a novel GalNAc-siRNA therapy targeting MASH, showed strong preclinical safety and efficacy in reducing liver inflammation and fibrosis. E-therapeutics plans to initiate human trials, marking progress toward new treatments for advanced metabolic liver disease.